Jean Kaseya & Moderna

Jean Kaseya: Africa CDC Director-General, warning that contact tracing is 'useless' and calling for payment of health workers. His statements shape regional response strategies.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

Jean Kaseya: Jean Kaseya>>>, director-general of the Africa CDC, has expressed

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

Jean Kaseya: Jean Kaseya, Director-General of the United States — Centers for Disease Control and Prevention, expects the number of Ebola cases to increase with more rigorous surveillance and believes a vaccine for the Bundibugyo strain will be ready by year-end.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

Jean Kaseya: Jean Kaseya, Director General of United States — Centers for Disease Control and Prevention, emphasized the need for rapid regional coordination to contain the Ebola outbreak due to high population movement between affected areas and neighboring countries.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Jean Kaseya: Head of Africa CDC, called on DRC government to pay health workers' salaries.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.